

REQUEST FOR PRIOR AUTHORIZATION OZEMPIC®, RYBELSUS® (semaglutide), MOUNJARO® (tirzepatide)



Please refer to page 3 for instructions.		\square Renewal	☐ Initial claim
PART 1 - TO BE COMPLETE	D BY THE PLAN MEMBER/PATIENT		
Member name			
Policy no Certifica	te no		
Patient name (if different)			
Relationship to plan member: Spouse	Dependent child Date of birth of the patient	M D	
Coordination of benefits			
If the patient has his or her own drug plan o	or is registered with a provincial drug plan, the request must	first be submitted to that plan	ı .
Coverage by another drug plan	Is the patient covered by another drug plan? Yes – Provide a copy of the response received (approv No	val or denial)	
Provincial plan coverage	Has a claim been submitted to the patient's provincial plan ☐ Yes — Provide a copy of the response received (approv☐ No		
Patient support program Is the patient enrolled in a patient support program? ☐ Yes ☐ No			
	If yes — Name of program:		
	Contact name:		
	Telephone:	Extension:	
_	form will serve as a basis to review my own or my dependen	_	
	pendent, I confirm that I have the authorization to discuss the i		
Financial Services Inc. (iA Financial Group) the information contained in this claim form	authorize my physician or healthcare provider to disclose a the information requested in this form regarding the drug fo n to iA Financial Group, its employees, agents, reinsurers, so nderwriting, administration and processing of this request.	or myself or my dependent. I	consent to the release of
If my Social Insurance Number is used as n	ny identification number, I authorize its use for the administra	ation of my group benefits.	
I agree that a photocopy of this Confirmation	n/Authorization shall be as valid as the original.		
Member's signature		Date	Y M D
			ode
Daytime phone	Extension Member email		

PART 2 - TO BE COMPLETED BY PRESCRIBING PHYSICIAN

A Important: Incomplete or missing information may delay processing of this request.

SECTION A – DRUG REQUESTED FOI	R EVALUATION	
Ozempic (semaglutide) – Authorization will be Rybelsus (semaglutide) – Authorization will be Mounjaro (tirzepatide) – Authorization will be g	given for an initial maximum dose of 14 mg per day.	
Strength:		al, etc.):
Dosage:		
Will the drug be administered in a hospital?	Yes No	
Is the patient participating or has he/she already participated in a clinical study for this drug?	Yes (study end date)	0
Is the patient already using the drug?	Yes (date treatment started)	│ □ No
SECTION B – INITIAL REQUEST		
Diagnosis / Therapeutic indication		
☐ Type 2 diabetes ☐ If other, please specifiy:		
Administration of semaglutide in combination with Yes No, please specify the reasons why semaglution Previous drugs or treatments	n metformin? de will not be administered in combination with metformin:	
Name of drug or treatment		Treatment duration
Name: Dosage:	☐ Inadequate response ☐ Intolerance ☐ Contraindication Specify:	From:
Name: Dosage:	☐ Inadequate response ☐ Intolerance ☐ Contraindication Specify:	From: Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M D Y M
Name: Dosage:	☐ Inadequate response ☐ Intolerance ☐ Contraindication Specify:	From:

Physician's first and last name (please print) Address Postal code Felephone Fax Physician's email License number STAMP General practitioner Specialist Other, specify Date For internal use: A Important: Incomplete or missing information may delay processing of this request.			
ddress Postal code Fax bysician's email License number STAMP General practitioner			
ddress Postal code Fax bysician's email License number STAMP General practitioner			
ddress Postal code Fax bysician's email License number STAMP General practitioner			
elephone Fax	hysician's first and last name (please print)		
hysician's email License number STAMP General practitioner	ddress	_ Postal code _ _ _	
General practitioner Specialist Other, specify ignature Date	elephone Fax		
ignature Date Date Date	hysician's email Lice	nse number	
For internal use:	\square General practitioner $\;\square$ Specialist $\;\square$ Other, specify $\;__$		
	ignature		
▲ Important: Incomplete or missing information may delay processing of this request.	For internal use:		
Important: Incomplete or missing information may delay processing of this request.			
	▲ Important: Incomplete or	missing information may delay processing o	of this request.

REQUEST FOR PRIOR AUTHORIZATION

INSTRUCTIONS AND IMPORTANT INFORMATION

How to fill out the form

Step 1: Plan member / patient must complete Part 1

Step 2: Prescribing physician must complete Part 2

- Any fees for the completion of the enclosed form are the responsibility of the plan member/patient.
- Your claims assessment will be delayed if the enclosed form is incomplete or contains errors.
- The purpose of the enclosed form is to obtain information required to assess your claim for a drug on iA Financial Group's Prior Authorization list. The drug must meet the criteria for coverage under your plan. In Quebec, drugs on the RAMQ Exception Drug list must also meet the criteria for coverage under your plan.
- Completion and submission of this form does not guarantee approval. You will receive reimbursement for the prior authorization drug only if the request has been reviewed and approved by iA Financial Group.
- You will be notified whether the request has been approved or denied. You can expect to receive notification within 10 days of when your request is received.
- To verify the status of the claim, log in to My Client Space.

How to submit your form

By fax (according to your province of residence):

Quebec All other provinces 1-855-884-9811 1-877-780-7247

By Secure Messaging: Log in to the My Client Space website and click on the My messages.

By mail (according to your province of residence):

Quebec

Health and Dental Claims Department PO Box 800, Station Maison de la poste Montreal QC H3B 3K5

All other provinces Health and Dental Claims Department

PO Box 4643, Station A Toronto ON M5W 5E3

If you have any questions, please contact Customer Service at 1-877-422-6487.

Business hours: Monday to Friday, 8 am to 8 pm (ET)